The abstract is read at the publisher; the summary is JClub's.
RNA therapeutics encompass multiple RNA modalities and have gained momentum after SARS-CoV-2 mRNA vaccine success, accelerating clinical translation for diseases with limited options.
- Why it matters: The field seeks faster, cheaper development and simpler manufacturing than small-molecule drugs, protein drugs, or gene therapies while addressing a broad disease spectrum.
- What they did: The review describes RNA approaches including antisense oligonucleotides, small interfering RNAs, microRNAs, mRNAs, and aptamers, highlighting translation driven by SARS-CoV-2 vaccine outcomes.
- The result: Accelerated research and clinical uptake are reported for chronic wounds, aggressive metastatic melanoma, and autoimmune and genetic skin diseases, expanding where RNA medicines may be applied.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.